Myelofibrosis Treatment Market Size, Share 2019 Global Industry Analysis by Trends, Opportunities, Segmentation, Business Growth, Future Plans and Regional Forecast to 2026
Global Myelofibrosis Treatment Market – Insights
Myelofibrosis is rare type of bone marrow cancer that is characterized by development of fibrous or scar tissue in the bone marrow and disruption in the body’s normal production of blood cells. The condition is more common in individuals aged over 50 years. Primary myelofibrosis and secondary myelofibrosis are the two types of the disease. The availability of therapies for the treatment myelofibrosis is low. Jakafi (Ruxolitinib) by Novartis is the only U.S. FDA approved (in 2011) drug for the treatment of myelofibrosis.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/721
Global Myelofibrosis Treatment Market: Drivers
High incidence of myelofibrosis, increasing investment in R&D of mew drugs, favorable reimbursement policies, and growing smoking population are some of the factors boosting growth of the global myelofibrosis market over the forecast period. For instance, the development of a molecule, CYT387 or Momelotinib, by Gilead Sciences for the treatment of primary myelofibrosis and ruxolitinib, by Incyte Corporation as a substitute dosing strategy in patients with myelofibrosis.
Global Myelofibrosis Treatment Market: Restraints
However, the high cost and low awareness of novel therapies is expected to hinder growth of the global myelofibrosis treatment market.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/721
Global Myelofibrosis Treatment Market Taxonomy
The global myelofibrosis treatment market is segmented on the basis of diagnosis, treatment, end user, and geography.
On the basis of diagnosis, the global myelofibrosis treatment market is segmented into:
- Gene Mutation Analysis
- Bone Marrow Biopsy
- Imaging Tests
- Blood Tests
On the basis of treatment, the global myelofibrosis treatment market is segmented into:
- Blood Transfusions
- Stem Cell Transplant
- Radiation Therapy
On the basis of end-user, the global myelofibrosis treatment market is segmented into:
- Bone Marrow Transplant Centers
On the basis of region, the global myelofibrosis treatment market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/721
Global Myelofibrosis Treatment Market: Regional Analysis
North America is expected to hold dominant position in the global myelofibrosis treatment market over the forecast period. This is attributed to high prevalence of myelofibrosis, favorable reimbursement policies, and increasing expenditure in the healthcare sector. For instance, according to the American Society of Hematology 2016, myelofibrosis affected around 20,000 people in the U.S.
Increasing disposable income, high geriatric population, and developing healthcare sector is expected to boost growth of the market in Asia Pacific.
Global Myelofibrosis Treatment Market: Competitive Landscape
Major players operating in the global myelofibrosis treatment market include, Celgene, Amgen, Bristol-Myers Squibb, Novartis, Eli Lilly, Roche, Merck & Co., Incyte Corporation, and Gilead Sciences.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/myelofibrosis-treatment-market-721
Key players in the market are focused on product development to expand their product portfolio. For instance, in 2016, Biopharma developed Pacritinib, which proved to be more effective than ruxolitinib.
Table of Content
Global Myelofibrosis Treatment Market Research Report
Section 1: Global Myelofibrosis Treatment Industry Overview
Section 2: Global Economic Impact on Myelofibrosis Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Myelofibrosis Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Myelofibrosis Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire